Aernoud T L Fiolet
Overview
Explore the profile of Aernoud T L Fiolet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Houwen J, Lalmohamed A, Zwaan J, Egberts T, Duyvendak M, Fiolet A, et al.
Eur J Clin Pharmacol
. 2025 Mar;
PMID: 40053073
Background: Low-dose (0.5 mg/day) colchicine improves cardiovascular outcomes in patients with stable coronary disease. Around 10-15% of these patients simultaneously use anticoagulant therapy, including vitamin-K antagonists (VKAs). In vitro studies...
2.
van der Bijl M, van der Veen J, Fiolet A, Boersma E, Cornel J, Eikelboom J, et al.
J Am Heart Assoc
. 2025 Feb;
14(5):e040412.
PMID: 39996509
No abstract available.
3.
4.
Mohammadnia N, van Broekhoven A, Bax W, Eikelboom J, Mosterd A, Fiolet A, et al.
Eur J Prev Cardiol
. 2024 Oct;
PMID: 39478683
Aims: Inflammatory lipoprotein(a) [Lp(a)] and oxidized phospholipids (OxPLs) on lipoproteins convey residual cardiovascular disease risk. The LoDoCo2 (low-dose colchicine 2) trial showed that colchicine reduced the risk for cardiovascular events...
5.
Fiolet A, Poorthuis M, Opstal T, Amarenco P, Boczar K, Buysschaert I, et al.
EClinicalMedicine
. 2024 Oct;
76:102835.
PMID: 39431112
Background: Guidelines recommend low-dose colchicine for secondary prevention in cardiovascular disease, but uncertainty remains concerning its efficacy for stroke, efficacy in key subgroups and about uncommon but serious safety outcomes....
6.
Poorthuis M, Hageman S, Fiolet A, Kappelle L, Bots M, Steg P, et al.
Stroke
. 2024 Sep;
55(11):2632-2640.
PMID: 39319460
Background: Risk models to identify patients at high risk of asymptomatic carotid artery stenosis (ACAS) can help in selecting patients for screening, but long-term outcomes in these patients are unknown....
7.
Fiolet A, Keusters W, Blokzijl J, Nidorf S, Eikelboom J, Eikelboom J, et al.
Eur Heart J Qual Care Clin Outcomes
. 2024 Mar;
11(1):89-96.
PMID: 38486357
Aims: Recent trials have shown that low-dose colchicine (0.5 mg once daily) reduces major cardiovascular events in patients with acute and chronic coronary syndromes. We aimed to estimate the cost-effectiveness...
8.
Mohammadnia N, Los J, Opstal T, Fiolet A, Eikelboom J, Mosterd A, et al.
Front Cardiovasc Med
. 2023 Oct;
10:1244529.
PMID: 37868776
Introduction: Despite optimal treatment, patients with chronic coronary artery disease (CAD) and diabetes mellitus (DM) are at high risk of cardiovascular events, emphasizing the need for new treatment options. The...
9.
Burger P, Koudstaal S, Mosterd A, Fiolet A, Teraa M, van der Meer M, et al.
J Am Coll Cardiol
. 2023 Jul;
82(5):414-426.
PMID: 37495278
Background: Patients with established cardiovascular disease (CVD) are at high risk of incident heart failure (HF), which may in part reflect the impact of systemic inflammation. Objectives: The goal of...
10.
Burger P, Dorresteijn J, Fiolet A, Koudstaal S, Eikelboom J, Nidorf S, et al.
Eur J Prev Cardiol
. 2023 Jul;
30(18):1950-1962.
PMID: 37409348
Aims: Low-dose colchicine reduces cardiovascular risk in patients with coronary artery disease (CAD), but absolute benefits may vary between individuals. This study aimed to assess the range of individual absolute...